Published in Br J Cancer on December 13, 2004
International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol (2011) 21.49
Lung cancer chemoprevention with celecoxib in former smokers. Cancer Prev Res (Phila) (2011) 1.77
Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. Br J Cancer (2008) 1.46
Preferential Allele Expression Analysis Identifies Shared Germline and Somatic Driver Genes in Advanced Ovarian Cancer. PLoS Genet (2016) 1.39
Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables. Ther Adv Med Oncol (2011) 1.32
Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J Clin Pathol (2006) 1.31
Biological activity of celecoxib in the bronchial epithelium of current and former smokers. Cancer Prev Res (Phila) (2010) 1.15
Prognostic value of CD133 expression in stage I lung adenocarcinomas. Int J Clin Exp Pathol (2010) 1.14
Tumour cell proliferation (Ki-67) in non-small cell lung cancer: a critical reappraisal of its prognostic role. Br J Cancer (2014) 1.08
Has Cox-2 a prognostic role in non-small-cell lung cancer? A systematic review of the literature with meta-analysis of the survival results. Br J Cancer (2006) 0.99
Cell proliferation, cell cycle abnormalities, and cancer outcome in patients with Barrett's esophagus: a long-term prospective study. Clin Cancer Res (2008) 0.98
Prognostic value of p53 and Ki67 expression in fiberoptic bronchial biopsies of patients with non small cell lung cancer. Multidiscip Respir Med (2012) 0.94
PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis. Transl Lung Cancer Res (2015) 0.94
Imaging of proliferation with 18F-FLT PET/CT versus 18F-FDG PET/CT in non-small-cell lung cancer. Eur J Nucl Med Mol Imaging (2010) 0.92
MTBP is overexpressed in triple-negative breast cancer and contributes to its growth and survival. Mol Cancer Res (2014) 0.92
Prognostic value of COX-2 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis. J Thorac Dis (2013) 0.92
Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinib. PLoS One (2013) 0.90
High NOTCH activity induces radiation resistance in non small cell lung cancer. Radiother Oncol (2013) 0.87
Downregulation of the CXCR4 receptor inhibits cervical carcinoma metastatic behavior in vitro and in vivo. Int J Oncol (2014) 0.85
Pretreatment SUVmax predicts progression-free survival in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy. Radiat Oncol (2014) 0.85
Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in surgically resectable stage III non-small cell lung cancer. Exp Ther Med (2010) 0.85
High Ki-67 Immunohistochemical Reactivity Correlates With Poor Prognosis in Bladder Carcinoma: A Comprehensive Meta-Analysis with 13,053 Patients Involved. Medicine (Baltimore) (2016) 0.85
Prognostic value of serum cytokeratin 19 fragments (Cyfra 21-1) in patients with non-small cell lung cancer. Sci Rep (2015) 0.84
Imaging proliferation of ¹⁸F-FLT PET/CT correlated with the expression of microvessel density of tumour tissue in non-small-cell lung cancer. Eur J Nucl Med Mol Imaging (2012) 0.84
Ki-67 as a prognostic marker in early-stage non-small cell lung cancer in Asian patients: a meta-analysis of published studies involving 32 studies. BMC Cancer (2015) 0.83
Assessing efficacy in early-phase cancer prevention clinical trials: the case of ki-67 in the lung. Cancer Prev Res (Phila) (2010) 0.83
Membrane-bound estrogen receptor-α expression and epidermal growth factor receptor mutation are associated with a poor prognosis in lung adenocarcinoma patients. World J Surg Oncol (2012) 0.83
What is better/reliable, mitosis counting or Ki67/MIB1 staining? Transl Lung Cancer Res (2016) 0.82
Clinicopathological and prognostic significance of high Ki-67 labeling index in hepatocellular carcinoma patients: a meta-analysis. Int J Clin Exp Med (2015) 0.82
OTUB1 triggers lung cancer development by inhibiting RAS monoubiquitination. EMBO Mol Med (2016) 0.82
Integrins and their ligands are expressed in non-small cell lung cancer but not correlated with parameters of disease progression. Virchows Arch (2013) 0.81
Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma. Br J Cancer (2015) 0.81
The prognostic role of Ki-67/MIB-1 in cervical cancer: a systematic review with meta-analysis. Med Sci Monit (2015) 0.81
Ki-67 expression in pulmonary tumors. Transl Lung Cancer Res (2016) 0.79
Difference in prognostic values of maximal standardized uptake value on fluorodeoxyglucose-positron emission tomography and cyclooxygenase-2 expression between lung adenocarcinoma and squamous cell carcinoma. World J Surg Oncol (2014) 0.78
[Diagnosis, prognosis, and prediction of non-small cell lung cancer : Importance of morphology, immunohistochemistry and molecular pathology]. Pathologe (2015) 0.77
The nucleolar protein NIFK promotes cancer progression via CK1α/β-catenin in metastasis and Ki-67-dependent cell proliferation. Elife (2016) 0.77
Correlation between Semi-Quantitative (18)F-FDG PET/CT Parameters and Ki-67 Expression in Small Cell Lung Cancer. Nucl Med Mol Imaging (2016) 0.77
What is the Prognostic Significance of Ki-67 Positivity in Oral Squamous Cell Carcinoma? J Cancer (2016) 0.77
The role of SOX-2 on the survival of patients with non-small cell lung cancer. J Thorac Dis (2015) 0.76
Nek7 is overexpressed in hepatocellular carcinoma and promotes hepatocellular carcinoma cell proliferation in vitro and in vivo. Oncotarget (2016) 0.76
Correlation between the Ki-67 proliferation index and response to radiation therapy in small cell lung cancer. Radiat Oncol (2017) 0.75
Correlation of diffusion MRI with the Ki-67 index in non-small cell lung cancer. Radiol Oncol (2015) 0.75
Prognostic factors in resected lung carcinomas. EJC Suppl (2013) 0.75
Tumor lysis without syndrome in adenocarcinoma of the lung: Case report. Respir Med Case Rep (2013) 0.75
Interstitial Fluid Pressure Correlates Clinicopathological Factors of Lung Cancer. Ann Thorac Cardiovasc Surg (2015) 0.75
Short-term exposure to tobacco toxins alters expression of multiple proliferation gene markers in primary human bronchial epithelial cell cultures. J Oncol (2011) 0.75
Ki-67 labeling index affects tumor infiltration patterns of lung squamous cell carcinoma. Mol Med Rep (2015) 0.75
Tumor cell proliferation, proliferative index and mitotic count in lung cancer. Transl Lung Cancer Res (2016) 0.75
The effect of TTF-1 expression on ipsilateral mediastinal nodal (N2) metastases in primary adenocarcinoma of the lung. Contemp Oncol (Pozn) (2013) 0.75
Sex-related differences of urethane and sodium valproate effects on Ki-67 expression in urethane-induced lung tumors of mice. Exp Ther Med (2017) 0.75
Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med (1998) 19.07
Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis (1985) 19.03
The Ki-67 protein: from the known and the unknown. J Cell Physiol (2000) 16.48
The medical review article: state of the science. Ann Intern Med (1987) 11.57
G1 events and regulation of cell proliferation. Science (1989) 9.73
Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst (1994) 7.91
Language bias in randomised controlled trials published in English and German. Lancet (1997) 7.29
Meta-analysis of the literature or of individual patient data: is there a difference? Lancet (1993) 6.16
Dominoes and clocks: the union of two views of the cell cycle. Science (1989) 5.74
Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med (1999) 4.81
Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol (1991) 3.82
Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J (2001) 3.04
Immunoreactivity for thyroid transcription factor-1 in stage I non-small cell carcinomas of the lung. Am J Surg Pathol (2001) 2.42
Review: assessment of cell proliferation in histological material. J Clin Pathol (1990) 2.41
Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol (2000) 1.83
The role of mitomycin in the treatment of non-small cell lung cancer: a systematic review with meta-analysis of the literature. Br J Cancer (2001) 1.82
A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res (1995) 1.62
Cell proliferation kinetics in human solid tumors: relation to probability of metastatic dissemination and long-term survival. Radiother Oncol (1989) 1.60
The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur Respir J (2002) 1.57
Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer (2003) 1.54
Prognostic values of stromal proportion and PCNA, Ki-67, and p53 proteins in patients with resected adenocarcinoma of the lung. Mod Pathol (2000) 1.54
The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer (2002) 1.52
Method for grading breast cancer. J Clin Pathol (1993) 1.46
Prophylactic cranial irradiation in small cell lung cancer: a systematic review of the literature with meta-analysis. BMC Cancer (2001) 1.44
Prognostic value of angiogenesis in operable non-small cell lung cancer. J Pathol (1996) 1.42
Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: results from the Eastern Cooperative Oncology Group Companion Study, EST 4189. J Clin Oncol (2000) 1.42
Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. J Natl Cancer Inst (1989) 1.40
Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value. Cancer (2002) 1.39
Assessment of proliferative activity in breast cancer: MIB-1 immunohistochemistry versus mitotic figure count. Hum Pathol (1999) 1.38
DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. Int J Cancer (2000) 1.31
Expression of DNA topoisomerase IIalpha and topoisomerase IIbeta genes predicts survival and response to chemotherapy in patients with small cell lung cancer. Clin Cancer Res (1999) 1.31
Correlation between mitotic and Ki-67 labeling indices in paraffin-embedded carcinoma specimens. Hum Pathol (1998) 1.31
Expression of X-linked inhibitor of apoptosis as a novel prognostic marker in radically resected non-small cell lung cancer patients. Clin Cancer Res (2001) 1.30
Prognostic significance of p27KIP1 protein and ki-67 growth fraction in non-small cell lung cancers. Clin Cancer Res (2000) 1.30
A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer (2000) 1.27
Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor. J Clin Oncol (1995) 1.22
Ki-67 immunostaining and survival in operable lung cancer. Histopathology (1991) 1.22
MCM2 is an independent predictor of survival in patients with non-small-cell lung cancer. J Clin Oncol (2001) 1.21
Relationship of Ki-67 labeling index to DNA-ploidy, S-phase fraction, and outcome in prostate cancer treated with radiotherapy. Prostate (1999) 1.14
The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature. Br J Cancer (2003) 1.14
The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction. Cancer (1997) 1.11
A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg (1999) 1.10
S-phase fraction and breast cancer--a decade of experience. Breast Cancer Res Treat (1998) 1.08
Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer. Ann Thorac Surg (1996) 1.08
Ki-67 immunostaining and other prognostic factors including tobacco smoking in patients with resected nonsmall cell lung carcinoma. Cancer (2000) 1.06
[VEGF and survival of patients with lung cancer: a systematic literature review and meta-analysis]. Rev Mal Respir (2002) 1.05
Expression of cyclin D1, Ki-67 and PCNA in non-small cell lung cancer: prognostic significance and comparison with p53 and bcl-2. Acta Histochem (2000) 1.02
Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung. Biochim Biophys Acta (1995) 1.00
Comparison of Ki-67 equivalent antibodies. J Clin Pathol (2002) 0.97
Prognostic implication of Ki-67 immunostaining in treating subclinical pleural cancer found at thoracotomy in lung cancer patients. Ann Thorac Surg (2001) 0.95
Molecular biologic substaging of stage I lung cancer according to gender and histology. Ann Thorac Surg (2000) 0.94
Prognostic significance of the proliferation index in surgically resected non-small-cell lung cancer. Arch Surg (1993) 0.94
Prognostic significance of p53, Ki-67, VEGF and Glut-1 in resected stage I adenocarcinoma of the lung. Lung Cancer (2002) 0.94
High cyclin E and low p27/Kip1 expressions are potentially poor prognostic factors in lung adenocarcinoma patients. Lung Cancer (2001) 0.93
Biological prognostic factors for early stage completely resected non-small cell lung cancer. J Surg Oncol (2000) 0.92
Prognostic value of MIB-1 in neuroendocrine tumours of the lung. J Pathol (1996) 0.91
Topoisomerase IIalpha and other drug resistance markers in advanced non-small cell lung cancer. Lung Cancer (2001) 0.91
Blood vessel invasion in resected non small cell lung carcinomas is predictive of metastatic occurrence. Lung Cancer (2002) 0.90
C-erbB-2 oncoprotein expression in operable non-small cell lung cancer. Anticancer Res (1996) 0.89
Phase II and III studies with new drugs for non-small cell lung cancer: a systematic review of the literature with a methodology quality assessment. Anticancer Res (2000) 0.88
Determination of proliferation index in neoplasms using different Ki-67 equivalent antibodies. APMIS (2003) 0.87
Typical and atypical bronchopulmonary carcinoid tumors: a clinicopathologic and KI-67-labeling study. Hum Pathol (1995) 0.85
Predicting prognosis in lung cancer: use of proliferation marker, Ki67 monoclonal antibody. J Pak Med Assoc (1998) 0.84
Proliferating cell nuclear antigen and Ki-67 in lung carcinoma. Correlation with DNA flow cytometric analysis. Cancer (1994) 0.84
Prognostic and predictive value of intratumoral microvessels density in operable non-small-cell lung cancer. Lung Cancer (1999) 0.84
Cell-cycle analysis detecting endogenous nuclear antigens: comparison with BrdU-in vivo labeling and an application to lung tumors. Acta Pathol Jpn (1993) 0.84
Neural networks as a prognostic tool for patients with non-small cell carcinoma of the lung. Mod Pathol (1997) 0.84
[Ki-67, marker of proliferation]. Ann Pathol (1997) 0.84
Hypodiploidy, Ki-67 growth fraction and prognosis of surgically resected lung cancers. Br J Cancer (1996) 0.83
Prognostic value of various staging and grading systems in proximal colon cancer. Eur J Surg (2002) 0.81
Recurrence and death in non-small cell lung carcinomas: a prognostic model using pathological parameters, microvessel count, and gene protein products. Clin Cancer Res (1996) 0.81
Low levels of p27 in association with deregulated p53-pRb protein status enhance tumor proliferation and chromosomal instability in non-small cell lung carcinomas. Mol Med (2001) 0.80
[Ki-67 antigen, a cell cycle and tumor growth marker]. Pathol Biol (Paris) (1991) 0.80
Prognostic biomarker study in pathologically staged N1 non-small cell lung cancer. Int J Radiat Oncol Biol Phys (1998) 0.80
Prognostic significance of Ki-67 immunostaining and symptoms in resected stage I and II non-small cell lung cancer. Lung Cancer (1998) 0.80
Tumor cell proliferation in prostate cancer after 3 months of neoadjuvant LHRH analogue treatment is a prognostic marker of recurrence after radical prostatectomy. Urology (1999) 0.80
Useful prognostic panel markers to express the biological tumor status in resected lung adenocarcinomas. Jpn J Clin Oncol (2000) 0.80
[Proliferation rate of small cell lung carcinoma. A cytomorphometric parameter with prognostic significance]. Pathologe (2001) 0.80
Combined analysis of MIB-1 and thyroid transcription factor-1 predicts survival in non-small cell lung carcinomas. Cancer Lett (2001) 0.79
[Prognostic factors on surgical treatment for lung cancer]. Kyobu Geka (2003) 0.79
Ploidy, proliferative activity, p53 and bcl-2 expression in bronchopulmonary carcinoids: relationship with prognosis. Pathol Res Pract (1999) 0.78
Biological markers in non-small cell lung cancer. Retrospective study of 10 year follow-up after surgery. J Cardiovasc Surg (Torino) (2002) 0.78
[Mulivariate analysis of prognostic factors in non-small cell lung cancer]. Zhonghua Yi Xue Za Zhi (1997) 0.77
[Preliminary study on relationship among apoptosis and related gene, prognosis of lung cancer]. Zhonghua Jie He He Hu Xi Za Zhi (1997) 0.77
Balance between cell division and cell death as predictor of survival in patients with non-small-cell lung cancer. Oncology (2002) 0.77
[Assessment of metastatic potential of pulmonary carcinoma]. Rozhl Chir (2000) 0.76
Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer (2007) 4.44
The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol (2000) 3.69
The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer (2005) 3.40
Psychosocial correlates of oestrogen and progesterone receptors in breast cancer. Lancet (1990) 3.14
ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy). Eur Respir J (2009) 3.08
Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J (2001) 3.04
Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol (2002) 3.03
Maintenance chemotherapy for small cell lung cancer: a critical review of the literature. Lung Cancer (1998) 2.27
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J (2009) 2.21
Association between antifungal prophylaxis and rate of documented bacteremia in febrile neutropenic cancer patients. Clin Infect Dis (2001) 2.03
Thyroid transcription factor 1--a new prognostic factor in lung cancer: a meta-analysis. Ann Oncol (2006) 1.92
Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature. Lung Cancer (2005) 1.92
The role of mitomycin in the treatment of non-small cell lung cancer: a systematic review with meta-analysis of the literature. Br J Cancer (2001) 1.82
Scoring systems in cancer patients admitted for an acute complication in a medical intensive care unit. Crit Care Med (2000) 1.69
The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur Respir J (2002) 1.57
Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents (2007) 1.57
Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer (2003) 1.54
The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer (2002) 1.52
CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients. Br J Cancer (2004) 1.52
Prophylactic cranial irradiation in small cell lung cancer: a systematic review of the literature with meta-analysis. BMC Cancer (2001) 1.44
Role of granulocyte and granulocyte-macrophage colony-stimulating factors in the treatment of small-cell lung cancer: a systematic review of the literature with methodological assessment and meta-analysis. Lung Cancer (2002) 1.40
[EGF-R expression correlation between biopsy and surgical specimens of lung carcinoma]. Rev Mal Respir (2003) 1.39
[Mechanical ventilation in the cancer patient]. Rev Mal Respir (2001) 1.39
[Endobronchial ultrasound and PET positive mediastinal lymph nodes]. Rev Mal Respir (2006) 1.38
Risk of anastomotic leakage with non-steroidal anti-inflammatory drugs in colorectal surgery. Br J Surg (2012) 1.31
Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother (1995) 1.31
A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer (2000) 1.27
Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br J Cancer (2008) 1.27
A prospective study on hyponatraemia in medical cancer patients: epidemiology, aetiology and differential diagnosis. Support Care Cancer (2000) 1.26
Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. J Clin Oncol (2001) 1.26
Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries. Ann Oncol (2011) 1.24
Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes. Ann Oncol (2001) 1.23
Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy. Ann Oncol (2011) 1.19
The effects of a 24-h psychological training program on attitudes, communication skills and occupational stress in oncology: a randomised study. Eur J Cancer (1993) 1.18
Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 cases. Am J Clin Pathol (2000) 1.15
The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature. Br J Cancer (2003) 1.14
Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer (2002) 1.13
HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Breast Cancer Res Treat (2004) 1.12
Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study. Bone Marrow Transplant (2010) 1.11
Subcutaneous lymphoid hyperplasia arising at site of ethnic scarifications and mimicking subcutaneous panniculitis-like T-cell lymphoma. Virchows Arch (2001) 1.09
A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignancies. Ann Oncol (2009) 1.08
Response to chemotherapy, quality of life benefits and survival in advanced non-small cell lung cancer: review of literature results. Lung Cancer (2001) 1.08
Screening for psychiatric disorders in a lymphoma out-patient population. Eur J Cancer (1992) 1.08
HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann Oncol (2001) 1.07
p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial. Ann Oncol (2007) 1.06
The landscape of medical oncology in Europe by 2020. Ann Oncol (2014) 1.05
[VEGF and survival of patients with lung cancer: a systematic literature review and meta-analysis]. Rev Mal Respir (2002) 1.05
Severe pericardial effusion in patients with concurrent malignancy: a retrospective analysis of prognostic factors influencing survival. Ann Surg Oncol (2008) 1.05
Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer. Int J Oncol (2004) 1.04
Interleukins-6 and -11 expression in primary breast cancer and subsequent development of bone metastases. Cancer Lett (2001) 1.03
Pretreatment minimal staging and prognostic factors for non-small cell lung cancer. Lung Cancer (1997) 1.01
Citation indexes do not reflect methodological quality in lung cancer randomised trials. Ann Oncol (2003) 1.01
Has Cox-2 a prognostic role in non-small-cell lung cancer? A systematic review of the literature with meta-analysis of the survival results. Br J Cancer (2006) 0.99